CurrentBlue Cross Blue Shield - IowaPolicy N/A

Airway Clearance Devices in the Home Setting

Defines medical necessity, investigational status, and replacement criteria for airway clearance devices used in the home setting for patients with hypersecretory lung disease or respiratory conditions related to neuromuscular disorders. Applies to clinical determinations for Blue Cross Blue Shield - Iowa (Wellmark) members.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyAirway Clearance Devices in the Home Setting

Policy CodePolicy N/A

Change TypeAnnual Review

Effective DateFebruary 1995

Next Review DateSeptember 2025

Key ActionDocument failure or intolerance of standard chest physiotherapy and submit clinical rationale with expected measurable outcomes over a minimum 3-month period when requesting coverage or prior authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

39 RCTsRandomized trials in systematic review

InsufficientEvidence quality

PresentReplacement criteria

RequiredDocumentation checklist

0 studies

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Combo systems evidence

Coverage Criteria and Evidence Context

High-frequency chest wall compression / Vibralung

Covered when ALL of the following are met:

High-frequency chest wall compression medical necessity

Eligible diagnoses: (1) Chronic diffuse bronchiectasis with either daily productive cough for at least six continuous months OR exacerbations requiring antibiotic therapy more than two times a year AND confirmed by high-resolution or spiral chest CT; OR (2) Cystic fibrosis; OR (3) Neurodegenerative/neuromuscular disease with documented respiratory muscle weakness or diaphragm paralysis.
General requirement: Documentation of failure of standard treatments and recurrent disease exacerbations (see Policy Guidelines).

Vibralung-specific: Vibralung (HCPCS E1399) may be medically necessary when the above criteria for a high-frequency chest wall compression device are met AND the individual is unable to use another high-frequency chest wall compression device (e.g., burns, chest trauma, rib fractures).

Oscillatory positive expiratory pressure devices

Covered when ALL of the following are met:

Oscillatory PEP medical necessity: Device may be considered medically necessary in individuals who have difficulty clearing secretions and recurrent disease exacerbations who have been diagnosed with bronchiectasis, COPD with excessive secretions (including chronic bronchitis), or cystic fibrosis.

HCPCS codes: E0484, S8185 where applicable

Mechanical insufflation-exsufflation devices

Covered when ALL of the following are met:

MI-E medical necessity: Device may be considered medically necessary for an individual with: (1) a neuromuscular disease (eg, muscular dystrophy, multiple sclerosis, amyotrophic lateral sclerosis, high spinal cord injury); AND (2) significant chest wall impairment and/or diaphragmatic movement; AND (3) documentation of failure of standard treatments.

HCPCS code: E0482

Replacement policy

Replacement covered when ONE of the following is met:

Replacement allowed: (1) Member meets medical necessity criteria for the specific device AND documentation confirms existing device is malfunctioning, no longer under warranty, and cannot be repaired; OR (2) Member meets medical necessity criteria AND provider documents replacement needed due to growth or change in condition.

HCPCS replacement codes include A7025, A7026

Replacement not allowed: Replacement is not medically necessary when the above replacement criteria are not met or when replacement is solely for better technology or improved aesthetics.

Coverage criteria for airway clearance devices

Covered when ALL of the following are met

Primary documentation: Documentation of one or more: caregiver physically or mentally incapable of performing chest physiotherapy as prescribed; no caregiver available to perform CPT as prescribed; CPT not tolerated; OR failure of CPT to adequately mobilize retained secretions despite being performed as prescribed.

Failure defined as repeat respiratory infections or decreased breathing capacity with documented CPT compliance.

Clinical features: Have difficulty clearing secretions AND have recurrent disease exacerbations (acute onset requiring additional treatment more than two times per year).>2/year

Cystic Fibrosis — Conditional coverage considerations (evidence mixed/inconclusive; device use may be considered when...)

Coverage considerations reflect that randomized and systematic-review evidence is mixed and inconclusive; device use may be considered when certain conditions are met.

CF coverage considerations: Use may be considered when: (1) patient has cystic fibrosis; (2) device is intended for home use as an alternative or adjunct to standard chest physical therapy; (3) clinical documentation demonstrates need and rationale (e.g., intolerance or inadequate response to standard therapy); and (4) expected benefit is to reduce symptoms, sputum burden, hospitalizations, or medication use over a minimum meaningful period (≥3 months).minimum meaningful period: 3 months

Supported by multiple small RCTs and a Cochrane review concluding no established superiority and need for adequately powered long-term RCTs.

Bronchiectasis — Conditional coverage considerations (mirror CF; depend on clinical justification)

Coverage considerations for bronchiectasis mirror those for CF and depend on clinical justification.

Bronchiectasis coverage considerations: Use may be considered when: (1) patient has bronchiectasis; (2) device is intended for home use as an alternative or adjunct to standard chest physical therapy; and (3) documentation shows prior use of or intolerance to standard chest physiotherapy and expected benefit over ≥3 months.minimum meaningful period: 3 months

Derived from PICO and bronchiectasis evidence review.

Bronchiectasis - Evidence Context

Considered when evaluating airway clearance devices for bronchiectasis:

Bronchiectasis - evidence context: Device is an oscillatory PEP airway clearance device intended for home use; patient diagnosed with bronchiectasis; comparator is standard chest physical therapy; outcomes of interest include exacerbations, hospitalizations, quality of life, and medication use with at least 3 months follow-up.minimum 3 months follow-up for meaningful outcome change

Randomized and crossover trials available but limited; only one trial reported exacerbations/hospitalizations and QoL results are mixed.

COPD - Evidence Context

Considered when evaluating airway clearance devices for COPD:

COPD - evidence context: Device is an airway clearance device intended for home use; patient diagnosed with COPD; comparator is standard therapy; outcomes of interest include exacerbations, hospitalizations, quality of life, and medication use with at least 3 months follow-up.minimum 3 months follow-up for meaningful outcome change

Only a few controlled studies exist and published studies reported mixed findings that do not support routine use for COPD.

Coverage considerations and evidence context

Coverage should consider the following clinical context and evidence:

Clinical population: Device intended for individuals with respiratory conditions related to neuromuscular disorders (specified population of interest).

From PICO population

COPD evidence: For COPD, only a few controlled studies exist with mixed findings; evidence does not support routine use of oscillatory devices for COPD.

Use caution for COPD coverage

Outcome documentation: Providers should document meaningful improvement in respiratory symptoms, quality of life, hospitalization rates, or medication use over >=3 months.>=3 months

Minimum meaningful period

Evidence-based coverage considerations

Coverage considerations should reflect the limited and mixed evidence; list when device use may be supported:

Supported scenarios (conditional): Device use may be considered when there is clinical rationale for airway clearance in patients with neuromuscular or related respiratory conditions and when measurable outcomes (eg, reduced hospitalizations, fewer exacerbations, improved quality of life) are expected and documented over a minimum 3-month period.minimum 3 months

Evidence includes small RCTs and systematic reviews suggesting improvements in immediate measures but limited data on long-term clinical outcomes; MI-E has HTA C rating.

Devices lacking adequate evidence

Devices or device combinations with insufficient evidence for improved health outcomes:

Not adequately supported: Combination HFCWO+PEP systems (eg, Metaneb) have no adequately powered studies showing improved health outcomes; coverage should require strong justification or be considered investigational unless other evidence provided.

Explicit statement that no adequately powered studies were identified.

General coverage rationale

Evidence summary and coverage stance

Evidence requirements: No adequately powered studies demonstrating that combination HFCWO+PEP systems (e.g., Metaneb) improve clinical outcomes; OLE systems (Volara, BiWaze) similarly lack adequately powered clinical outcome studies.

Identified studies did not evaluate clinical outcomes of interest; one study evaluated only aerosol delivery efficiency.

Guideline considerations

Supplemental clinical input

Guideline-informed considerations: Specialty input suggests oscillatory devices may be an alternative to chest physical therapy for cystic fibrosis when patients fail or are intolerant of other methods; ACCP and Cystic Fibrosis Foundation recommend individualized airway clearance selection. NICE recommends not offering HFCWO for cystic fibrosis except in exceptional circumstances.

These are advisory and reflect limited/conflicting evidence.

Airway clearance devices that do not meet the policy’s specified medical necessity criteria are designated investigational. Examples explicitly listed in the policy include combination high-frequency chest oscillation and positive expiratory pressure systems (e.g., MetaNeb) and oscillation lung expansion devices (e.g., Volara, BiWaze Clear), because available evidence is insufficient to demonstrate improved net health outcomes.

This policy and evidence review apply to devices intended for outpatient/home use only. Inpatient device use (for example, in the immediate postsurgical period) is not addressed by this policy.

The policy does not enumerate extensive explicit exclusion clauses; however, systematic reviews and RCT summaries emphasize heterogeneous, limited, and inconclusive evidence for superiority of oscillatory devices versus standard chest physical therapy. That lack of clear superiority and the mixed quality of data may be used to deny routine coverage in the absence of specific clinical justification.

During evidence selection, studies with duplicative or overlapping patient populations were excluded. This approach can influence which trials inform coverage decisions and may lead to exclusion of certain evidence when populations overlap.

For chronic obstructive pulmonary disease (COPD), the published controlled studies are few and report mixed findings. The policy notes that the available trials did not support routine use of oscillatory airway clearance devices for COPD, and therefore routine coverage for COPD is not supported without stronger evidence or individual justification.

Combination systems that integrate high-frequency chest wall oscillation with positive expiratory pressure (e.g., MetaNeb) have no adequately powered clinical studies demonstrating improved patient-centered outcomes. As a result, these systems are considered investigational and may be excluded from coverage or require individualized clinical rationale and supporting evidence for consideration.

Clinical input and guideline sources included in the review did not support routine use of oscillatory devices for COPD. Specialty input indicated oscillatory devices may be considered alternatives to chest physiotherapy in CF or bronchiectasis when patients fail or are intolerant of other methods, while NICE specifically advises against offering high-frequency chest wall oscillation for cystic fibrosis except in exceptional circumstances.

The policy does not list specific CPT procedure codes for provider services related to device use. Providers must report services using appropriate CPT, HCPCS, revenue, and ICD diagnosis codes as applicable when submitting claims or prior authorization requests.

Replacement requests that are submitted solely for improved technology or aesthetics are considered not medically necessary. Replacement will be denied when the policy’s replacement criteria are not met.

Provision of an airway clearance device as a substitute when standard chest physiotherapy (CPT) has not been attempted or documented as performed as prescribed does not meet the policy’s requirement for failure of standard treatments and would not satisfy medical necessity criteria.

Routine provision of oscillatory airway clearance devices without clinical documentation of prior trial or failure of standard chest physical therapy may be considered not medically necessary, given systematic reviews and RCTs that did not establish superiority over standard therapies.

The body of trial evidence is limited and mixed—many small randomized controlled trials, crossover designs, and few trials reporting clinically important outcomes—so routine use is constrained by the quality and quantity of available data.

Use of oscillatory airway clearance devices for COPD without supporting clinical evidence demonstrating benefit for the individual patient may be not medically necessary and could be denied in the absence of stronger clinical justification.

Use of any oscillatory combination systems or other airway clearance devices when there is no reasonable expectation of measurable clinical benefit (for example, without documentation of prior standard therapy trial and expected outcomes over a minimum meaningful period) may be considered not medically necessary due to insufficient evidence.

Devices lacking adequately powered evidence to show improved clinical outcomes are identified in the policy. Named examples include combination HFCWO+PEP systems (e.g., MetaNeb) and Oscillation Lung Expansion (OLE) systems (e.g., Volara, BiWaze Clear) and these are treated as investigational or not medically necessary when used expecting demonstrable clinical benefit without supporting trials.

HCPCS and Supply Codes

Covered HCPCS for high-frequency devicesHCPCSCovered

E0483	High-frequency chest wall compression/oscillator
E1399	Durable medical equipment, miscellaneous (Vibralung® acoustical percussor)

Covered HCPCS for oscillatory PEP devicesHCPCSCovered

E0484	Oscillatory positive expiratory pressure device
S8185	Oscillatory positive expiratory pressure device (alternate code)

Covered HCPCS for MI-E devicesHCPCSCovered

E0482

Mechanical insufflation-exsufflation device

Replacement device codesHCPCSCovered

A7025	Replacement part/code for airway clearance devices
A7026	Replacement part/code for airway clearance devices

Investigational device examplesmixedExperimental

No codes listed

Codes table referencedmixed

No codes listed

HCPCS Device and supply codesHCPCSCovered

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter).
A7025	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each.
A7026	High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each.
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device.
E0482	High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each.
E0483	Oscillatory positive expiratory pressure device, non-electric, any type, each.
E0484	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each.
E1399	Durable medical equipment, miscellaneous.
S8185	Flutter device.

inv-37: Recurrent disease exacerbations — more than two times a year

CriterionRecurrent disease exacerbations defined as acute onset requiring additional treatment more than two times per year

ContextRequired for medical necessity of HFCWO and oscillatory PEP devices when documenting failure of standard treatments

Documentation expectationExacerbations should be clearly described (e.g., antibiotic courses, hospitalizations) in submitted clinical records

inv-38: Chronic productive cough duration — daily productive cough for at least six continuous months

Duration threshold

Prior Authorization, Documentation, and Denial Risks

Prior Authorization

Coverage requires documented medical necessity

Coverage for home airway clearance devices requires documented medical necessity. Prior authorization is required and requests must include documentation that supports medical necessity, the specific device requested, the treated diagnosis, and prior or concurrent standard therapy and outcomes. Claims and authorizations must use the HCPCS codes listed in the Codes section.

Coverage requires documented medical necessity.
Prior authorization required for home airway clearance devices used in the home setting.
Use listed HCPCS codes when requesting coverage or prior authorization.

Prior Authorization

Prior authorization: diagnosis and prior therapy

Prior authorization must document the treated diagnosis (e.g., cystic fibrosis, chronic diffuse bronchiectasis confirmed by high-resolution CT, or neuromuscular/ neurodegenerative disease with respiratory muscle weakness) and evidence of prior therapy. When applicable, include documentation of trials and failure or intolerance of standard chest physiotherapy (CPT) or reason CPT is not feasible (caregiver unavailable or incapable).

Background and Scope

Airway clearance devices provide alternatives to manual chest percussion and postural drainage for patients with excessive mucus production or impaired cough. Device classes discussed include high-frequency chest wall compression vests, oscillatory positive expiratory pressure devices, and mechanical insufflation-exsufflation systems; these are primarily intended for home use as an alternative to standard chest physiotherapy.

Key Definitions and Device Types

inv-75: High-frequency chest wall compression/oscillator — HCPCS E0483 definition and brief description

HCPCS codeE0483 — High-frequency chest wall compression/oscillator (vest/oscillator)

DescriptionExternal oscillatory compression delivered by an inflatable vest or oscillator to assist mucus clearance

Typical useIntended for home airway clearance as an alternative to chest physiotherapy

inv-76: Oscillatory (vibratory) positive expiratory pressure device — handheld/portable device definition (HCPCS E0484/S8185)

HCPCS codesE0484 and S8185 — Oscillatory (vibratory) positive expiratory pressure devices

Device typeHandheld or portable devices that create oscillations during exhalation to mobilize secretions (examples: Flutter, Acapella)

Policy History and Revisions

September 2025Annual review / Policy renewedLatest

Policy renewed following annual review (September 2025).

September 2024Annual review / Policy revised

Policy revised after annual review (September 2024).

August 2023Annual review / Policy renewed

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyAirway Clearance Devices in the Home Setting

Policy CodePolicy N/A

Change TypeAnnual Review

Effective DateFebruary 1995

Next Review DateSeptember 2025

SourceLink

On This Page

Setting: Device intended primarily for home use by the individual.

Documented in request

Daily productive cough for at least six continuous months

Associated diagnosisSpecifically referenced for chronic diffuse bronchiectasis eligibility

Supporting confirmationShould be combined with imaging confirmation (high-resolution or spiral chest CT) when used for HFCWO criteria

inv-39: Recurrent disease exacerbations — more than two times a year (duplicate index grouping)

Criterion (duplicate)Recurrent disease exacerbations defined as acute onset warranting additional treatment >2 times/year

Use in policyApplied across device classes (HFCWO, OPEP) as part of coverage requirements when CPT has failed

Evidence requirementClinical records must show frequency and treatments for exacerbations to substantiate this threshold

inv-40: Forced Vital Capacity (FVC) — >= 40% predicted (inclusion criterion in one RCT)

Threshold>= 40% predicted FVC (inclusion criterion in one randomized controlled trial)

Subgroup noteSubgroup analyses in the trial examined patients with FVC 40–70% predicted

ContextCriterion used in exploratory RCT of HFCWO in neuromuscular disease (ALS), 12-week duration

inv-41: Minimum outcome assessment period — >= 3 months

Minimum period>= 3 months (minimum meaningful outcome assessment period)

Outcomes to assessRespiratory symptoms, quality of life, hospitalizations, and medication use should be evaluated over this period

Documentation implicationPrior authorization and follow-up should specify measurable outcomes assessed at or after 3 months

Diagnoses to document: Cystic fibrosis; chronic diffuse bronchiectasis (confirmed by HRCT); neuromuscular disease with respiratory muscle weakness or diaphragm paralysis.
Document prior trial of standard chest physiotherapy when feasible and reasons for failure or inability to perform CPT.

Prior Authorization

Home airway clearance device PA

For home airway clearance device prior authorization, indicate the device type (e.g., oscillatory PEP, high-frequency chest wall oscillation vest, mechanical insufflation-exsufflation, Vibralung®) and that the device is for home use. Specify the treated condition and include the clinical rationale for device use over standard therapy.

Specify device model/type and that it is intended for home use.
State the treated condition (e.g., bronchiectasis, cystic fibrosis, neuromuscular disease).
Provide clinical rationale for device as alternative to or replacement for CPT.

Documentation Required

Population and setting requirement

Identify the targeted population and setting: airway clearance devices considered under this policy are intended for individuals with appropriate respiratory conditions (e.g., CF, bronchiectasis, neuromuscular-related respiratory weakness) and for use primarily in the home setting.

Target population: individuals with CF, chronic diffuse bronchiectasis, or neuromuscular/ neurodegenerative diseases with respiratory muscle weakness.
Place of service: home use only.

Prior Authorization

Prior authorization recommended

Prior authorization is recommended to include a clinical rationale, documentation of prior standard therapy trials (or reasons standard therapy was not feasible), and the expected measurable outcomes over a defined period (minimum meaningful period = 3 months).

Provide expected measurable outcomes and timeframe (consider ≥ 3 months).
Document prior/concurrent standard therapy and adherence when applicable.

Documentation Required

Prior authorization requirements

Required clinical documentation for medical necessity and prior authorization includes: indication (diagnosis), prior and/or concurrent standard therapy with dates and adherence, reasons CPT failed or was not feasible (e.g., caregiver incapable or unavailable, intolerance), and objective or functional outcome measures to demonstrate benefit.

Document indication and confirming diagnostic evidence (e.g., HRCT for bronchiectasis).
Document prior trial of CPT performed as prescribed or reason CPT not performed (caregiver incapacity/unavailability or intolerance).
Provide history of recurrent exacerbations or failure of standard treatments.
Include outcome measures and plan to reassess effectiveness (minimum 3 months).

Billing Rule

HCPCS codes required for claims/authorization

When submitting claims or requests for prior authorization, use the HCPCS codes listed in the policy Codes section for reporting DME and device supplies. Ensure provider services are reported with appropriate CPT or other applicable codes per billing guidance.

Use HCPCS codes from the policy Codes section (e.g., E0482, E0483, E0469, A7021, A7025, A7026, E1399 where applicable).
Confirm correct coding for provider services to avoid coding-related denials.

Denial Risk

Evidence selection exclusion risk

Study selection excluded duplicative or overlapping populations; exclusion of relevant studies or selection of low-quality evidence may affect coverage decisions. Be aware that limited or low-quality evidence for certain indications (e.g., COPD, combination HFCWO+PEP systems) may lead to denials or classify requests as not medically necessary.

Studies with overlapping populations were excluded from evidence review.
Mixed or insufficient evidence for COPD and certain combination systems may result in noncoverage.

Documentation Required

Documentation should include indication

Documentation should include the clinical indication (e.g., neuromuscular disease with respiratory muscle weakness, cystic fibrosis, bronchiectasis), prior and concurrent therapies, objective outcome measures (e.g., frequency of exacerbations, hospitalizations, medication use, quality of life measures), and the planned period for assessing response (minimum meaningful change period ~3 months).

Indication and diagnostic confirmation (e.g., HRCT for bronchiectasis).
Prior/concurrent therapies and adherence documentation.
Baseline and follow-up outcome measures with planned reassessment timeframe (≥ 3 months).

Note

Policy history & submissions

Retain the policy history and submit new information or technology relevant to the policy review to the payer contact listed in the policy history. This helps ensure updated evidence or new device technologies are considered in future reviews.

Policy history retained; see policy for prior review dates and actions.
Submit new information to Wellmark Blue Cross and Blue Shield Medical Policy Analyst, PO Box 9232, Des Moines, IA 50306-9232.

Step Therapy

Step: CPT first when feasible

When feasible, a trial of standard chest physiotherapy (CPT) should be performed before approving an airway clearance device. Document that CPT was performed as prescribed and the clinical response, or document why CPT was not feasible (e.g., intolerance, lack of caregiver).

Require evidence of CPT trial and outcome when feasible.
If CPT not performed, provide documentation of caregiver incapacity, intolerance, or unavailability.

Step Therapy

Step-through standard chest physical therapy

Prior authorization should document stepwise care demonstrating trials of standard chest physical therapy and why device therapy is being considered (failure, intolerance, or caregiver limitations). The comparator is standard chest physical therapy; provide documentation of prior use and comparative rationale.

Comparator therapy: standard chest physical therapy.
Document trials of CPT and reason device is required as alternative.

Step Therapy

Comparator requirement

Comparator requirement: standard chest physiotherapy (for bronchiectasis) or standard therapy (for other conditions such as COPD or neuromuscular disease) is the comparator for device therapy. Documentation should explain why standard therapy is insufficient or why a device is expected to provide measurable benefit.

Comparator: standard chest physiotherapy or standard therapy.
Explain insufficiency of standard therapy or expected benefit from device.

Step Therapy

Standard therapy comparator

Standard therapy comparator: clearly indicate prior use of chest physiotherapy or other established standard therapy, and provide clinical evidence demonstrating failure, intolerance, or impracticality of standard therapy to justify device use.

Document attempts at standard therapy and outcomes.
If standard therapy failed or was not tolerated, provide specific evidence (e.g., recurrent infections, inability to clear secretions).

Step Therapy

Step therapy logic — standard chest physiotherapy

Step-therapy logic: standard chest physiotherapy or other established standard therapy is the primary comparator and should generally be tried before device approval; exceptions must be documented (e.g., burns, chest trauma, rib fractures, caregiver inability).

Require trial of standard therapy before device except when contraindicated or not feasible.
Document the exception with clinical justification.

Step Therapy

Step therapy considerations

Step therapy considerations: airway clearance devices are alternatives to chest physiotherapy and may be considered when patients have failed, are intolerant of, or are unable to perform CPT. Provide caregiver capability documentation and objective measures for follow-up.

Devices considered when CPT has failed, is unavailable, or not tolerated.
Document caregiver incapacity or unavailability when applicable.
Provide plan for measurable follow-up outcomes (≥ 3 months).

SettingIntended for patient self-use in the home for airway clearance

inv-77: Mechanical insufflation-exsufflation (MI-E) — device definition (HCPCS E0482)

HCPCS codeE0482 — Mechanical insufflation-exsufflation (MI-E) device

FunctionDelivers positive pressure followed by rapid negative pressure to simulate cough and clear secretions (cough augmentation)

IndicationsUsed primarily in neuromuscular disease with cough impairment; evidence includes systematic reviews and HTA assessments

inv-78: Chest physiotherapy (CPT) — definition and role as standard of care

DefinitionChest physiotherapy (CPT) — use of postural drainage, percussion, and vibration (PDPV) for airway clearance

RoleConsidered the standard of care for secretion clearance and the primary comparator for device therapies

LimitationsMay be time-consuming, requires skilled caregiver, and can be associated with discomfort or hypoxemia

inv-79: Failure of Standard of Treatments — definition including repeat infections or decreased breathing capacity with evidence of CPT adherence

DefinitionFailure of standard treatments: includes repeat respiratory infections or decreased breathing capacity despite documented, consistent performance of chest physiotherapy as prescribed

Evidence requiredProvider must document CPT adherence and that infections or decreased function occurred despite CPT

ImplicationFailure of standard treatments is a prerequisite for device medical necessity per policy

inv-80: Bronchiectasis — definition

DefinitionBronchiectasis — disorder of major bronchi and bronchioles with abnormal airway dilatation and destruction leading to mucus accumulation and recurrent infections

Clinical relevanceLeads to difficulty clearing secretions and is a primary diagnosis considered for airway clearance devices

Diagnostic confirmationPolicy requires imaging confirmation (high-resolution or spiral chest CT) when used for HFCWO criteria

inv-81: Cystic fibrosis (CF) — definition

DefinitionCystic fibrosis (CF) — autosomal recessive condition causing production of excessive tenacious tracheobronchial mucus leading to airway obstruction and secondary infection

Policy contextCF is an eligible diagnosis for oscillatory devices and HFCWO when other criteria (e.g., recurrent exacerbations) are met

Therapeutic goalDevice use aims to reduce symptoms, sputum burden, hospitalizations, or medication use over a meaningful period

inv-82: Airway clearance device — definition (oscillatory PEP, Vibralung, etc.)

DefinitionAirway clearance device — devices such as oscillatory PEP devices and the Vibralung intended for patient self-use in the home to facilitate mucus clearance

ExamplesIncludes handheld OPEP devices (Flutter, Acapella), HFCWO vests, Vibralung acoustical percussor, and MI-E devices

Intended settingPrimarily for outpatient/home use by the individual

inv-83: Therapy purpose — provide alternative to existing airway clearance therapies for CF or bronchiectasis

PurposeProvide an alternative to or improvement on existing airway clearance therapies for individuals with CF or bronchiectasis

Use-caseConsidered when patients have difficulty clearing secretions or have failed/intolerant of standard CPT

Expected benefitsTarget outcomes include reduced symptoms, sputum burden, hospitalizations, or medication use over >=3 months

inv-84: oscillatory PEP airway clearance device — definition and function

DefinitionOscillatory PEP airway clearance device — device that produces oscillations during exhalation to assist mucus mobilization and clearance

MechanismCreates positive expiratory pressure with superimposed oscillations during exhalation to loosen secretions

Clinical study populationsStudied in CF, bronchiectasis, and COPD populations as alternatives to CPT

inv-85: minimum meaningful duration — Meaningful outcome interval: minimum 3-month period

Minimum meaningful durationMinimum 3-month period to assess clinically meaningful changes in outcomes

RationalePolicy specifies outcomes (symptoms, QOL, hospitalizations, medication use) should be assessed over at least 3 months

ApplicationUsed for prior authorization follow-up and to determine if device provides expected benefit

inv-86: Airway clearance devices — devices intended for primary use in the home setting

Intended settingAirway clearance devices intended for primary use in the home setting by the individual

DocumentationRequests should state device is for home use and describe home-care circumstances

Exclusion notePolicy applies to outpatient/home use only and does not address inpatient device use

inv-87: Meaningful outcome period — minimum 3 months for outcome changes

Meaningful outcome periodMinimum 3 months for outcome changes to be considered meaningful

Outcomes to documentRespiratory symptoms, quality of life, hospitalizations, and medication use over the period

Informing coverage decisionsDemonstrated improvement over this period supports continued coverage or replacement

inv-88: HFCWO — High-frequency chest wall oscillation definition

DefinitionHigh-frequency chest wall oscillation (HFCWO) — external chest wall oscillation delivered by a vest system to mobilize secretions

Evidence contextReferenced in multiple randomized trials and device summaries; studied in CF, neuromuscular disease, and COPD

Typical codingHCPCS E0483

inv-89: MI-E (CoughAssist) — Mechanical insufflation-exsufflation definition and HTA rating context

DefinitionMechanical insufflation-exsufflation (MIE/MI-E) — cough augmentation device delivering positive then negative pressure to simulate cough and clear secretions

Evidence/HTAAssessed in systematic reviews; Hayes HTA rated C (potential but unproven benefit) for CoughAssist MI-E

Typical codingHCPCS E0482

inv-90: Combination HFCWO+PEP (e.g., Metaneb) — definition and note on lack of adequately powered studies

DefinitionCombination HFCWO+PEP systems (e.g., Metaneb) — devices that combine high-frequency chest wall oscillation with positive expiratory pressure therapy

Evidence gapNo adequately powered clinical outcome studies identified demonstrating improved health outcomes

Policy implicationConsidered investigational or requiring strong justification in coverage decisions

inv-91: OLE — Oscillation Lung Expansion therapy definition

DefinitionOscillation Lung Expansion (OLE) therapy — an oscillatory modality considered as an alternative or improvement on existing airway clearance therapies

Intended useApplied for respiratory conditions including those related to neuromuscular disorders, intended for home use

EvidenceLimited; few adequately powered clinical outcome studies identified

inv-92: OLE — Oscillation Lung Expansion (alternate index)

Alternate labelOLE — Oscillation Lung Expansion

ContextConsidered in policy as a named modality with limited outcome evidence (e.g., Volara, BiWaze)

Policy stanceDevices lacking adequately powered outcome studies are considered investigational absent strong justification

inv-93: Combination HFCWC+PEP — combination systems examples (Metaneb)

ExamplesCombination HFCWO+PEP systems: Metaneb (example cited)

DescriptionSystems integrate chest wall oscillation with intrapulmonary percussive ventilation or PEP functions

Evidence notePolicy identifies no adequately powered studies demonstrating improved clinical outcomes for these combinations

inv-94: HFCWO — definition and references in randomized trials and device summaries

DefinitionHFCWO — external chest wall oscillation delivered by a vest system to mobilize secretions

Trial referencesReferenced in randomized trials (e.g., McIlwaine 2013; Lange 2006) and device summaries in the literature

Clinical useUsed in CF, bronchiectasis, COPD, and neuromuscular populations as an alternative to CPT

inv-95: Mechanical insufflation-exsufflation (MIE) — cough augmentation device definition and physiologic support

DefinitionMechanical insufflation-exsufflation (MIE) — cough augmentation device that provides positive then negative airway pressure to simulate cough and clear secretions

Physiologic supportShown to improve peak cough flow in systematic reviews and small RCTs; long-term clinical outcome data limited

Clinical contextsUsed in neuromuscular disease, critical care, and home settings for patients with impaired cough

inv-96: Oscillatory positive expiratory pressure (OPEP) — device creating oscillatory PEP; studied in CF, bronchiectasis, COPD

DefinitionOscillatory positive expiratory pressure (OPEP) — device that creates oscillatory PEP during exhalation to mobilize sputum

MechanismProduces oscillations superimposed on expiratory pressure to loosen and mobilize secretions

Study populationsStudied in cystic fibrosis, bronchiectasis, and COPD populations; coded as E0484/S8185

Policy renewed following annual review (August 2023).

January 2023Annual review / Policy revised

Policy revised after annual review (January 2023).

January 2022Annual review / Policy revised

Policy revised after annual review (January 2022).

January 2021Annual review / Policy revised

Policy revised after annual review (January 2021).

January 2020Annual review / Policy revised

Policy revised after annual review (January 2020).

September 2019Annual review / Policy revised

Policy revised after annual review (September 2019).

September 2018Annual review / Policy revised

Policy revised after annual review (September 2018).

September 2017Annual review / Policy revised

Policy revised after annual review (September 2017).

May 2017Annual review / Policy revised

Policy revised after annual review (May 2017).

May 2016Annual review / Policy revised

Policy revised after annual review (May 2016).

June 2015Annual review / Policy revised

Policy revised after annual review (June 2015).

July 2014Annual review / Policy revised

Policy revised after annual review (July 2014).

September 2013Annual review / Policy revised

Policy revised after annual review (September 2013).

October 2012Annual review / Policy renewed

Policy renewed following annual review (October 2012).

November 2011Annual review / Policy revised

Policy revised after annual review (November 2011).

October 2010Annual review / Policy renewed

Policy renewed following annual review (October 2010).